Antleron

Foundation date

21/11/2014

Sector

#Biotechnology / R&D Services

Therapeutic areas

We are Antleron, a nimble team that will revolutionise medicine by leading the development of next generation advanced therapies and medical devices. By merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors we will accelerate the engineering of medicinal products, devices and processes that will change health care and result in a better life for all. The Antleron business philosophy is to create sustainable ventures through risk & reward sharing partnerships.

Upcoming events

Latest news

  • argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia

    20 hours ago

  • Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

    Wednesday November 22nd 2023

  • argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis

    Thursday November 16th 2023